Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of$98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue guidance of$530 million to $550 million Breakthrough Designation granted for setrusumab (UX143) in osteogenesis imperfecta DTX401 Phase 3 follow-up data demonstrated higher and faster 62% mean reduction in cornstarch in crossover patients with glycogen storage disease type Ia (GSDIa) NOVATO, Calif., Nov. 05, 2024 ( ...